Everolimus-eluting stent curbs thrombosis, mortality risk in diabetes

11/29/2012 | Healio

Diabetes patients who were implanted with a second-generation everolimus-eluting stent showed lower stent thrombosis rates and all-cause mortality compared with those who had first-generation sirolimus-eluting and paclitaxel-eluting stents, a study indicated. The results appear in the Journal of the American College of Cardiology: Cardiovascular Interventions.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT